Development and evaluation of a machine learning-based in-hospital COvid-19 disease outcome predictor (CODOP): a multicontinental retrospective study
- University of Turku, Finland
- Max Planck Institute of Experimental Medicine, Germany
- University of Malaga, Spain
- General University Hospital of Alicante, Spain
- Gregorio Marañón University Hospital, Spain
- Hospital Universitario 12 De Octubre, Spain
- Hospital Costa del Sol, Spain
- Hospital Británico of Buenos Aires, Argentina
- Hospital Santa Cruz - Caja Petrolera de Salud, Bolivia
- Hospital of San Juan de Dios, Bolivia
- Hospital Honduras Medical Centre, Honduras
- Hospital Velez Sarsfield, Argentina
- Hospital Italiano de Buenos Aires, Argentina
- Clausthal University of Technology, Germany
- Max Planck Institute for Experimental Medicine, Germany
Abstract
New SARS-CoV-2 variants, breakthrough infections, waning immunity, and sub-optimal vaccination rates account for surges of hospitalizations and deaths. There is an urgent need for clinically valuable and generalizable triage tools assisting the allocation of hospital resources, particularly in resource-limited countries. We developed and validate CODOP, a machine learning-based tool for predicting the clinical outcome of hospitalized COVID-19 patients. CODOP was trained, tested and validated with six cohorts encompassing 29223 COVID-19 patients from more than 150 hospitals in Spain, the USA and Latin America during 2020-22. CODOP uses 12 clinical parameters commonly measured at hospital admission for reaching high discriminative ability up to nine days before clinical resolution (AUROC: 0·90-0·96), it is well calibrated, and it enables an effective dynamic risk stratification during hospitalization. Furthermore, CODOP maintains its predictive ability independently of the virus variant and the vaccination status. To reckon with the fluctuating pressure levels in hospitals during the pandemic, we offer two online CODOP calculators, suited for undertriage or overtriage scenarios, validated with a cohort of patients from 42 hospitals in three Latin American countries (78-100% sensitivity and 89-97% specificity). The performance of CODOP in heterogeneous and geographically disperse patient cohorts and the easiness of use strongly suggest its clinical utility, particularly in resource-limited countries.
Data availability
The raw patient data used in this study are not freely available due to legal restrictions of the ethical committees of the different hospitals. However, they can be accessed upon request to the Scientific Committees of these organisms. An exception to this is the patient data from the USA cohort, which has been published elsewhere. All the model's numerical data necessary to generate all figures can be found in the submitted source data tables. Furthermore, all supplementary tables can be found in Supplementary File 1.
Article and author information
Author details
Juan Miguel Antón-Santos
Jose Manuel Ramos-Rincon
David Gómez-Varela
Funding
Max Planck Society (Publication cost)
- David Gómez-Varela
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2022, Klén et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,453
- views
-
- 277
- downloads
-
- 6
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Development and evaluation of a machine learning-based in-hospital COvid-19 disease outcome predictor (CODOP): a multicontinental retrospective study
eLife 11:e75985.
https://doi.org/10.7554/eLife.75985
Further reading
-
- Epidemiology and Global Health
- Medicine
- Microbiology and Infectious Disease
eLife has published the following articles on SARS-CoV-2 and COVID-19.
-
- Computational and Systems Biology
Plasmid construction is central to life science research, and sequence verification is arguably its costliest step. Long-read sequencing has emerged as a competitor to Sanger sequencing, with the principal benefit that whole plasmids can be sequenced in a single run. Nevertheless, the current cost of nanopore sequencing is still prohibitive for routine sequencing during plasmid construction. We develop a computational approach termed Simple Algorithm for Very Efficient Multiplexing of Oxford Nanopore Experiments for You (SAVEMONEY) that guides researchers to mix multiple plasmids and subsequently computationally de-mixes the resultant sequences. SAVEMONEY defines optimal mixtures in a pre-survey step, and following sequencing, executes a post-analysis workflow involving sequence classification, alignment, and consensus determination. By using Bayesian analysis with prior probability of expected plasmid construction error rate, high-confidence sequences can be obtained for each plasmid in the mixture. Plasmids differing by as little as two bases can be mixed as a single sample for nanopore sequencing, and routine multiplexing of even six plasmids per 180 reads can still maintain high accuracy of consensus sequencing. SAVEMONEY should further democratize whole-plasmid sequencing by nanopore and related technologies, driving down the effective cost of whole-plasmid sequencing to lower than that of a single Sanger sequencing run.
